Evaluation of Plaque Stability of Advanced Atherosclerotic Lesions in Apo E-Deficient Mice after Treatment with the Oral Factor Xa Inhibitor Rivaroxaban
Aim. Thrombin not only plays a central role in thrombus formation and platelet activation, but also in induction of inflammatory processes. Activated factor X (FXa) is traditionally known as an important player in the coagulation cascade responsible for thrombin generation. We assessed the hypothesi...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Hindawi Limited,
2011-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_7faae85d3ccb40d5a657ac6e76ab8a66 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Qianxing Zhou |e author |
| 700 | 1 | 0 | |a Florian Bea |e author |
| 700 | 1 | 0 | |a Michael Preusch |e author |
| 700 | 1 | 0 | |a Hongjie Wang |e author |
| 700 | 1 | 0 | |a Berend Isermann |e author |
| 700 | 1 | 0 | |a Khurrum Shahzad |e author |
| 700 | 1 | 0 | |a Hugo A. Katus |e author |
| 700 | 1 | 0 | |a Erwin Blessing |e author |
| 245 | 0 | 0 | |a Evaluation of Plaque Stability of Advanced Atherosclerotic Lesions in Apo E-Deficient Mice after Treatment with the Oral Factor Xa Inhibitor Rivaroxaban |
| 260 | |b Hindawi Limited, |c 2011-01-01T00:00:00Z. | ||
| 500 | |a 0962-9351 | ||
| 500 | |a 1466-1861 | ||
| 500 | |a 10.1155/2011/432080 | ||
| 520 | |a Aim. Thrombin not only plays a central role in thrombus formation and platelet activation, but also in induction of inflammatory processes. Activated factor X (FXa) is traditionally known as an important player in the coagulation cascade responsible for thrombin generation. We assessed the hypothesis that rivaroxaban, a direct FXa inhibitor, attenuates plaque progression and promotes stability of advanced atherosclerotic lesions in an in vivo model. Methods and Results. Rivaroxaban (1 or 5 mg/kg body weight/day) or standard chow diet was administered for 26 weeks to apolipoprotein E-deficient mice (n=20 per group) with already established atherosclerotic lesions. There was a nonsignificant reduction of lesion progression in the high-concentration group, compared to control mice. FXa inhibition with 5 mg Rivaroxaban/kg/day resulted in increased thickness of the protective fibrous caps (12.3±3.8 μm versus 10.1±2.7 μm; P<.05), as well as in fewer medial erosions and fewer lateral xanthomas, indicating plaque stabilizing properties. Real time-PCR from thoracic aortas revealed that rivaroxaban (5 mg/kg/day) treatment reduced mRNA expression of inflammatory mediators, such of IL-6, TNF-α, MCP-1, and Egr-1 (P<.05). Conclusions. Chronic administration of rivaroxaban does not affect lesion progression but downregulates expression of inflammatory mediators and promotes lesion stability in apolipoprotein E-deficient mice. | ||
| 546 | |a EN | ||
| 690 | |a Pathology | ||
| 690 | |a RB1-214 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Mediators of Inflammation, Vol 2011 (2011) | |
| 787 | 0 | |n http://dx.doi.org/10.1155/2011/432080 | |
| 787 | 0 | |n https://doaj.org/toc/0962-9351 | |
| 787 | 0 | |n https://doaj.org/toc/1466-1861 | |
| 856 | 4 | 1 | |u https://doaj.org/article/7faae85d3ccb40d5a657ac6e76ab8a66 |z Connect to this object online. |